BACKGROUND: TMPRSS2-ERG fusions have been identified in about one-half of all prostatic adenocarcinomas (PCas). Fluorescence in situ hybridization (FISH) and reverse transcription polymerase chain reaction have been the most commonly used techniques in this setting. The aim of this study was to evaluate the utility of ERG immunoexpression as a surrogate for TMPRSS2-ERG fusion in a large series of PCa cases. MATERIALS AND METHODS: Four hundred twenty-seven radical retropubic prostatectomy tissue samples were used to construct 10 tissue microarrays (TMAs). FISH analysis was previously conducted using dual-color interphase break-apart probes for the 5' and 3' regions of the ERG gene. ERG expression was evaluated using a commercial rabbit anti-ERG monoclonal antibody (clone EPR3864; Epitomics, Burlingame, CA). Each TMA spot was independently assessed, and any nuclear staining positivity was considered as indicative of ERG expression. RESULTS: TMPRSS2-ERG fusions were detected by FISH in 195 (45.7%) of the PCa cases. ERG immunoexpression was found in 192 (45.0%) of the PCa cases and in none of the nontumoral tissue samples. Mean ERG H-scores were significantly higher in tumors harboring FISH-detected TMPRSS2-ERG fusions (P<0.00001), and there was a strong association between ERG immunohistochemical expression and the TMPRSS2-ERG status defined by FISH (P<0.00001), with a sensitivity of 86% (95% CI, 80%-90%) and a specificity of 89% (95% CI, 84%-93%). Receiver-operating characteristic curve analysis showed that ERG immunoexpression had a high accuracy for identifying TMPRSS2-ERG fusions detected by FISH, with an area under the curve of 0.87 (95% CI, 0.84%-0.91; P<0.00001). CONCLUSIONS: We found that ERG immunohistochemical expression has a high accuracy for defining the TMPRSS-ERG fusion status. ERG immunohistochemistry may offer an accurate, simpler, and less costly alternative for evaluation of ERG fusion status in PCa than FISH.
BACKGROUND:TMPRSS2-ERG fusions have been identified in about one-half of all prostatic adenocarcinomas (PCas). Fluorescence in situ hybridization (FISH) and reverse transcription polymerase chain reaction have been the most commonly used techniques in this setting. The aim of this study was to evaluate the utility of ERG immunoexpression as a surrogate for TMPRSS2-ERG fusion in a large series of PCa cases. MATERIALS AND METHODS: Four hundred twenty-seven radical retropubic prostatectomy tissue samples were used to construct 10 tissue microarrays (TMAs). FISH analysis was previously conducted using dual-color interphase break-apart probes for the 5' and 3' regions of the ERG gene. ERG expression was evaluated using a commercial rabbit anti-ERG monoclonal antibody (clone EPR3864; Epitomics, Burlingame, CA). Each TMA spot was independently assessed, and any nuclear staining positivity was considered as indicative of ERG expression. RESULTS:TMPRSS2-ERG fusions were detected by FISH in 195 (45.7%) of the PCa cases. ERG immunoexpression was found in 192 (45.0%) of the PCa cases and in none of the nontumoral tissue samples. Mean ERG H-scores were significantly higher in tumors harboring FISH-detected TMPRSS2-ERG fusions (P<0.00001), and there was a strong association between ERG immunohistochemical expression and the TMPRSS2-ERG status defined by FISH (P<0.00001), with a sensitivity of 86% (95% CI, 80%-90%) and a specificity of 89% (95% CI, 84%-93%). Receiver-operating characteristic curve analysis showed that ERG immunoexpression had a high accuracy for identifying TMPRSS2-ERG fusions detected by FISH, with an area under the curve of 0.87 (95% CI, 0.84%-0.91; P<0.00001). CONCLUSIONS: We found that ERG immunohistochemical expression has a high accuracy for defining the TMPRSS-ERG fusion status. ERG immunohistochemistry may offer an accurate, simpler, and less costly alternative for evaluation of ERG fusion status in PCa than FISH.
Authors: Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan Journal: Science Date: 2005-10-28 Impact factor: 47.728
Authors: Maisa Yoshimoto; Anthony M Joshua; Susan Chilton-Macneill; Jane Bayani; Shamini Selvarajah; Andrew J Evans; Maria Zielenska; Jeremy A Squire Journal: Neoplasia Date: 2006-06 Impact factor: 5.715
Authors: Rohit Mehra; Bo Han; Scott A Tomlins; Lei Wang; Anjana Menon; Matthew J Wasco; Ronglai Shen; James E Montie; Arul M Chinnaiyan; Rajal B Shah Journal: Cancer Res Date: 2007-09-01 Impact factor: 12.701
Authors: Karin G Hermans; Ronald van Marion; Herman van Dekken; Guido Jenster; Wytske M van Weerden; Jan Trapman Journal: Cancer Res Date: 2006-11-15 Impact factor: 12.701
Authors: F Demichelis; K Fall; S Perner; O Andrén; F Schmidt; S R Setlur; Y Hoshida; J-M Mosquera; Y Pawitan; C Lee; H-O Adami; L A Mucci; P W Kantoff; S-O Andersson; A M Chinnaiyan; J-E Johansson; M A Rubin Journal: Oncogene Date: 2007-01-22 Impact factor: 9.867
Authors: Sven Perner; Juan-Miguel Mosquera; Francesca Demichelis; Matthias D Hofer; Pamela L Paris; Jeff Simko; Colin Collins; Tarek A Bismar; Arul M Chinnaiyan; Angelo M De Marzo; Mark A Rubin Journal: Am J Surg Pathol Date: 2007-06 Impact factor: 6.394
Authors: J Clark; S Merson; S Jhavar; P Flohr; S Edwards; C S Foster; R Eeles; F L Martin; D H Phillips; M Crundwell; T Christmas; A Thompson; C Fisher; G Kovacs; C S Cooper Journal: Oncogene Date: 2006-10-16 Impact factor: 9.867
Authors: Richard Flavin; Andreas Pettersson; Whitney K Hendrickson; Michelangelo Fiorentino; Stephen Finn; Lauren Kunz; Gregory L Judson; Rosina Lis; Dyane Bailey; Christopher Fiore; Elizabeth Nuttall; Neil E Martin; Edward Stack; Kathryn L Penney; Jennifer R Rider; Jennifer Sinnott; Christopher Sweeney; Howard D Sesso; Katja Fall; Edward Giovannucci; Philip Kantoff; Meir Stampfer; Massimo Loda; Lorelei A Mucci Journal: Clin Cancer Res Date: 2014-03-31 Impact factor: 12.531
Authors: Rebecca E Graff; Andreas Pettersson; Rosina T Lis; Natalie DuPre; Kristina M Jordahl; Elizabeth Nuttall; Jennifer R Rider; Michelangelo Fiorentino; Howard D Sesso; Stacey A Kenfield; Massimo Loda; Edward L Giovannucci; Bernard Rosner; Paul L Nguyen; Christopher J Sweeney; Lorelei A Mucci Journal: Prostate Date: 2015-03-01 Impact factor: 4.104
Authors: Cindy Ke Zhou; Denise Young; Edward D Yeboah; Sally B Coburn; Yao Tettey; Richard B Biritwum; Andrew A Adjei; Evelyn Tay; Shelley Niwa; Ann Truelove; Judith Welsh; James E Mensah; Robert N Hoover; Isabell A Sesterhenn; Ann W Hsing; Shiv Srivastava; Michael B Cook Journal: Am J Epidemiol Date: 2017-12-15 Impact factor: 4.897
Authors: Raymond B Nagle; Amit M Algotar; Connie C Cortez; Katherine Smith; Carol Jones; Ubaradka G Sathyanarayana; Steven Yun; Janice Riley; Dea Nagy; Ryan Dittamore; Bruce Dalkin; Laura Brosh; Gary Pestano Journal: Prostate Date: 2013-05-07 Impact factor: 4.104
Authors: Carlos L Morais; Mehsati Herawi; Antoun Toubaji; Roula Albadine; Jessica Hicks; George J Netto; Angelo M De Marzo; Jonathan I Epstein; Tamara L Lotan Journal: Prostate Date: 2015-07-14 Impact factor: 4.104
Authors: Steven P Rowe; Kenneth L Gage; Sheila F Faraj; Katarzyna J Macura; Toby C Cornish; Nilda Gonzalez-Roibon; Gunes Guner; Enrico Munari; Alan W Partin; Christian P Pavlovich; Misop Han; H Ballentine Carter; Trinity J Bivalacqua; Amanda Blackford; Daniel Holt; Robert F Dannals; George J Netto; Martin A Lodge; Ronnie C Mease; Martin G Pomper; Steve Y Cho Journal: J Nucl Med Date: 2015-06-11 Impact factor: 10.057
Authors: Liyan Xue; Xueying Mao; Guoping Ren; Elzbieta Stankiewicz; Sakunthala C Kudahetti; Dongmei Lin; Luis Beltran; Daniel M Berney; Yong-Jie Lu Journal: Am J Cancer Res Date: 2012-11-20 Impact factor: 6.166
Authors: Christopher Weier; Michael C Haffner; Timothy Mosbruger; David M Esopi; Jessica Hicks; Qizhi Zheng; Helen Fedor; William B Isaacs; Angelo M De Marzo; William G Nelson; Srinivasan Yegnasubramanian Journal: J Pathol Date: 2013-06 Impact factor: 7.996